Efficacy and safety of dupilumab in children aged ≥6 months to <6 years with moderate-to-severe atopic dermatitis

被引：0
|
作者：
Paller, Amy S.
Siegfried, Elaine C.
Simpson, Eric L.
Wollenberg, Andreas
Gonzalez, Mercedes E.
Sidbury, Robert
Lockshin, Benjamin
Xiao, Jing
O'Malley, John T.
Bansal, Ashish
机构：
来源：
ALLERGY AND ASTHMA PROCEEDINGS | 2022年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：561 / 561
页数：1
相关论文
共 50 条
  • [1] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, Amy S.
    Cork, Michael J.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sun, Yiping
    O'Malley, John T.
    Bansal, Ashish
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 187 : 12 - 12
  • [2] Efficacy and safety of dupilumab in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Simpson, E. L.
    Siegfried, E. C.
    Cork, M. J.
    Wollenberg, A.
    Arkwright, P. D.
    Soong, W.
    Gonzalez, M. E.
    Schneider, L. C.
    Sidbury, R.
    Lockshin, B.
    Wang, Z.
    Mannent, L. P.
    Amin, N.
    Sun, Y.
    Laws, E.
    Akinlade, B.
    Kosloski, M. P.
    Dubost-Brama, A.
    O'Malley, J. T.
    Bansal, A.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : E173 - E173
  • [3] EFFICACY AND SAFETY OF DUPILUMAB IN CHILDREN AGED 6 MONTHS TO 5 YEARS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS
    Worrell, Richard
    Paller, Amy S.
    Siegfried, Elaine C.
    Simpson, Eric L.
    Wollenberg, Andreas
    Gonzalez, Mercedes E.
    Sidbury, Robert
    Lockshin, Benjamin
    Dubost-Brama, Ariane
    Bansal, Ashish
    INTERNAL MEDICINE JOURNAL, 2022, 52 : 31 - 32
  • [4] DUPILUMAB REDUCES ITCH IN CHILDREN WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS AGED 6 MONTHS TO 5 YEARS
    Paller, A. S.
    Siegfried, E. C.
    Yosipovitch, G.
    Kwatra, S. G.
    Praestgaard, A.
    Prescilla, R.
    Wang, J.
    VALUE IN HEALTH, 2023, 26 (06) : S57 - S58
  • [5] Dupilumab Reduces Itch in Children with Moderate-to-Severe Atopic Dermatitis Aged 6 Months to 5 Years
    Paller, Amy S.
    Siegfried, Elaine C.
    Yosipovitch, Gil
    Kwatra, Shawn G.
    Praestgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB151 - AB151
  • [6] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Dillon, M.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2022, 142 (08) : S51 - S51
  • [7] Dupilumab Improves Family Quality of Life in Children Aged 6 months to 5 Years With Moderate-to-Severe Atopic Dermatitis
    Paller, Amy
    Simpson, Eric
    Siegfried, Elaine
    Preastgaard, Amy
    Wang, Zhixiao
    Prescilla, Randy
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (03) : AB150 - AB150
  • [8] Dupilumab Reduces Biomarkers Indicative of Type 2 Inflammation in Children Aged ≥ 6 Months to < 6 YearsWith Moderate-to-Severe Atopic Dermatitis
    Pinter, Andreas
    Paller, Amy
    Guttman-Yassky, Emma
    Boguniewicz, Mark
    Sun, Yiping
    Wolfe, Kelley
    Dillon, Myles
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 100 - 100
  • [9] Dupilumab reduces biomarkers indicative of type 2 inflammation in children aged ≥ 6 months to < 6 years with moderate-to-severe atopic dermatitis
    Paller, A. S.
    Guttman-Yassky, E.
    Boguniewicz, M.
    Sun, Y.
    Wolfe, K.
    Kroeller-Schoen, S.
    ALLERGOLOGIE, 2022, 45 (08) : 621 - 622
  • [10] 411 Long term laboratory safety of dupilumab in patients aged 6 months to 5 years with moderate-to-severe atopic dermatitis
    Siegfried, Elaine
    Cork, Michael J.
    Lockshin, Benjamin
    Boguniewicz, Mark
    Uppal, Sumeet
    Khokhar, Faisal A.
    Bansal, Ashish
    Sierka, Debra
    Cyr, Sonya
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
12345